Unibest

Pharmaceutical intermediates

Erlotinib Hydrochloride Intermediates

4 pharmaceutical intermediates for Erlotinib Hydrochloride. Indication: Non-small cell lung cancer; Pancreatic cancer.

提交项目All intermediates

About Erlotinib Hydrochloride

Originator
Genentech
Indication
Non-small cell lung cancer; Pancreatic cancer
Approved Date
11/18/2004

Available intermediates

4 intermediates currently listed for Erlotinib Hydrochloride. Request specifications, documentation or a quotation for any item below.

Erlotinib Hydrochloride intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
3-Ethynylaniline54060-30-9//
6,7-Bis-(2-methoxyethoxy)-4(3H)-quinazolinone179688-29-0//
2-Amino-4,5-bis(2-methoxyethoxy)benzoic acid ethyl ester hydrochloride183322-17-0//
4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline183322-18-1//

Other programs under E

Edoxaban tosylate monohydrateElacestrantElagolix SodiumEldecalcitolElinzanetantElobixibatEltrombopagEltrombopag Olamine

Building toward Erlotinib Hydrochloride?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →